$1.77
-0.12-6.19%
At close: -
$2.01
0.2413.37%
After Hours: Mar 27, 9:13 AM EDT
Comments
Loading...
Celularity Analyst Ratings and Price Targets | NASDAQ:CELU | Benzinga
Celularity Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Celularity Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Morgan Stanley
HC Wainwright & Co.
Alliance Global Partners
Truist Securities
1calculated from analyst ratings
Analyst Ratings for Celularity
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 01/30/2023 | Buy Now | — | Morgan Stanley | Jeffrey Hung55% | $50 → $10 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 01/30/2023 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth49% | $150 → $25 | Maintains | Buy | Get Alert |
| 12/22/2022 | Buy Now | — | Oppenheimer | Matthew Biegler36% | — | Downgrade | Outperform → Perform | Get Alert |
| 09/12/2022 | Buy Now | — | Morgan Stanley | Jeffrey Hung55% | $80 → $50 | Maintains | Equal-Weight | Get Alert |
| 08/25/2022 | Buy Now | — | Alliance Global Partners | James Molloy30% | → $150 | Initiates | → Buy | Get Alert |
| 08/23/2022 | Buy Now | — | Truist Securities | Asthika Goonewardene41% | $100 → $60 | Maintains | Hold | Get Alert |
| 06/22/2022 | Buy Now | — | HC Wainwright & Co. | Swayampakula Ramakanth49% | → $150 | Initiates | → Buy | Get Alert |
| 04/06/2022 | Buy Now | — | Truist Securities | Asthika Goonewardene41% | — | Downgrade | Buy → Hold | Get Alert |
FAQ
What is the target price for Celularity (CELU) stock?
The latest price target for Celularity (NASDAQ:CELU) was reported by Morgan Stanley on January 30, 2023. The analyst firm set a price target for $1.00 expecting CELU to fall to within 12 months (a possible -50.25% downside). 0 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Celularity (CELU)?
The latest analyst rating for Celularity (NASDAQ:CELU) was provided by Morgan Stanley, and Celularity downgraded their underweight rating.
When was the last upgrade for Celularity (CELU)?
There is no last upgrade for Celularity
When was the last downgrade for Celularity (CELU)?
The last downgrade for Celularity Inc happened on January 30, 2023 when Morgan Stanley changed their price target from $5 to $1 for Celularity Inc.
When is the next analyst rating going to be posted or updated for Celularity (CELU)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Celularity, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Celularity was filed on January 30, 2023 so you should expect the next rating to be made available sometime around January 30, 2024.
Is the Analyst Rating Celularity (CELU) correct?
While ratings are subjective and will change, the latest Celularity (CELU) rating was a downgraded with a price target of $5.00 to $1.00. The current price Celularity (CELU) is trading at is $2.01, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.